|
NPHP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.43190000043847E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.37839999994716E-06 |
| Normal-vs-Stage2 |
2.01040000002983E-06 |
| Normal-vs-Stage3 |
1.07820000039283E-07 |
| Normal-vs-Stage4 |
3.464100E-03 |
| Stage1-vs-Stage2 |
8.765500E-02 |
| Stage1-vs-Stage3 |
1.110260E-02 |
| Stage1-vs-Stage4 |
6.253000E-01 |
| Stage2-vs-Stage3 |
8.887600E-01 |
| Stage2-vs-Stage4 |
5.739600E-01 |
| Stage3-vs-Stage4 |
4.918000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.29229999946379E-07 |
| Normal-vs-AfricanAmerican |
6.916900E-03 |
| Normal-vs-Asian |
1.278960E-03 |
| Caucasian-vs-AfricanAmerican |
7.501600E-01 |
| Caucasian-vs-Asian |
5.712000E-01 |
| AfricanAmerican-vs-Asian |
9.179200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.806400E-04 |
| Normal-vs-Female |
6.10850003912589E-09 |
| Male-vs-Female |
3.706200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.150650E-04 |
| Normal-vs-Age(41-60Yrs) |
4.24520000041895E-07 |
| Normal-vs-Age(61-80Yrs) |
3.50290000000752E-05 |
| Normal-vs-Age(81-100Yrs) |
1.02000000001823E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.853400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.197550E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.062700E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.940400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.400200E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.835500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.95990000001678E-06 |
| Classical-VS-Follicular |
2.638600E-01 |
| Classical-VS-Other |
3.342200E-01 |
| Classical-VS-Normal |
4.45660000003567E-06 |
| Tall-VS-Follicular |
6.036000E-03 |
| Tall-VS-Other |
4.012200E-02 |
| Tall-VS-Normal |
7.279500335855E-10 |
| Follicular-VS-Other |
2.183400E-01 |
| Follicular-VS-Normal |
2.13999999999492E-05 |
| Other-VS-Normal |
4.263400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95920000223282E-08 |
| Normal-vs-N1 |
6.812200E-02 |
| N0-vs-N1 |
1.721210E-01 |
|
|
